BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38554302)

  • 1. Ewing's sarcoma in adolescents and adults - 10-year experience from a tertiary cancer center in India.
    Narayanan G; Kamala LH; Nair SG; Purushothaman PN; Kumar A; Kattoor J
    J Cancer Res Ther; 2024 Jan; 20(1):79-84. PubMed ID: 38554302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
    Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
    Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
    Argon A; Basaran M; Yaman F; Dizdar Y; Sakar B; Camlica H; Bavbek SE; Ozger H; Darendeliler E; Onat H
    Jpn J Clin Oncol; 2004 Nov; 34(11):667-72. PubMed ID: 15613556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    Dunst J; Ahrens S; Paulussen M; Rübe C; Winkelmann W; Zoubek A; Harms D; Jürgens H
    Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):379-84. PubMed ID: 9788419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and survival of 92 cases of Ewing's sarcoma family of tumor initially treated with multidisciplinary therapy].
    Peng RJ; Sun XF; Xiang XJ; Zhen ZJ; Ling JY; Tong GL; Xia Y; Xu GC; Jiang WQ
    Ai Zheng; 2009 Dec; 28(12):1304-9. PubMed ID: 19958626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
    N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Wexler LH; DeLaney TF; Tsokos M; Avila N; Steinberg SM; Weaver-McClure L; Jacobson J; Jarosinski P; Hijazi YM; Balis FM; Horowitz ME
    Cancer; 1996 Aug; 78(4):901-11. PubMed ID: 8756388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
    J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
    Corvest V; Marec-Bérard P; Lervat C; Pacquement H; Toulmonde M; Gentet JC; Laurence V; Cleirec M; Mansuy L; Bompas E; Castex MP; Taque S; Filhon B; Tabone MD; Verité C; Entz-Werle N; Saumet L; Guimard G; Pondrom M; Chevreau C; Flandrin J; Duranteau L; Rousset-Jablonski C; Brugières L; Jimenez M; Le Deley MC; Gaspar N; Fresneau B
    Int J Cancer; 2023 Apr; 152(8):1659-1667. PubMed ID: 36250317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
    Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
    Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
    Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
    Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
    Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
    Dunst J; Jürgens H; Sauer R; Pape H; Paulussen M; Winkelmann W; Rübe C
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):919-30. PubMed ID: 7607966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
    Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
    J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group.
    Donaldson SS; Torrey M; Link MP; Glicksman A; Gilula L; Laurie F; Manning J; Neff J; Reinus W; Thompson E; Shuster JJ
    Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):125-35. PubMed ID: 9747829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Kushner BH; Meyers PA
    J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
    Czyzewski EA; Goldman S; Mundt AJ; Nachman J; Rubin C; Hallahan DE
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):569-77. PubMed ID: 10348286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
    J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
    Ataergin S; Ozet A; Solchaga L; Turan M; Beyzadeoglu M; Oysul K; Arpaci F; Komurcu S; Surenkok S; Ozturk M
    Med Oncol; 2009; 26(3):276-86. PubMed ID: 18989798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
    Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
    J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.